FDA grants full approval for Inluriyo plus Verzenio in ESR1-mutated breast cancer
FDA granted full approval to Lilly’s Inluriyo (imlunestrant) plus Verzenio (abemaciclib) for adults with ER+, HER2—, ESR1— mutated advanced or metastatic breast cancer after at least one line of endocrine therapy, based on EMBER-3.